BioScene Informatics Inc. -- Japan Market Entry Consulting for the Life Sciences

CLC bio

CLC bio boasts as being the world's leading bioinformatics solution provider. Next Generation Sequencing is a major focus area and CLC bio delivers a comprehensive cross-platform analysis solution, which can analyze and visualize genomic, transcriptomic, and epigenomic data from all major platforms, like Illumina’s Genome Analyzer, SOLiD by Applied Biosystems, 454 by Roche, and HeliScope by Helicos.

BioScene helped CLC bio establish a Japanese face to its business under the brand CLC bio Japan. David Leangen was appointed founding CEO of CLC bio Japan and managed the initial distribution of all CLC bio products in Japan.

Testimonial from CLC bio

Although we try to be flexible when dealing with the various cultures around the world, we have found Japan to be a particularly difficult market to crack. David Leangen has shown to have very deep knowledge of the Japanese market. With the combination of our commitment to excellence and David's guidance as CEO of our newly-founded CLC bio Japan, we have seen significant growth in Japan in recent months and expect sales to continue to grow over the coming years.

Thomas Knudsen
CEO
CLC bio A/S